Clinical trials: Soft-tissue Sarcomas
Advanced Synovial Sarcoma
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-609 given…
- Trial name
- NCT04965753
- Testing
- FHD-609
- Where
- 12 sites in United States, France and 2 more
- Volunteers
- 55 people
- Sponsor
- Foghorn Therapeutics Inc.
Ewing Sarcoma, Myxoid Liposarcoma
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.
- Conditions
- Ewing Sarcoma, Myxoid Liposarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma
- Trial name
- NCT05266196
- Testing
- Seclidemstat
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Salarius Pharmaceuticals, LLC
Advanced Solid Tumor Cancer
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection.
- Trial name
- NCT04389281
- Testing
- X-PACT
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Immunolight, LLC
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma
L19IL2/L19TNF in Skin Cancer Patients
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.
- Conditions
- BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin
- Trial name
- IntriNSiC (NCT05329792)
- Testing
- L19IL2/L19TNF
- Where
- 14 sites in France, Italy and 1 more
- Volunteers
- 70 people
- Sponsor
- Philogen S.p.A.
Solid Tumor
Study in Advanced Solid Tumors
The primary purpose of this study is to help answer the following research question(s): To see how the body absorbs, processes, and gets rid of cetuximab when the drug is taken in combination with cisplatin [pharmacokinetic (PK)…
- Trial name
- NCT01099358
- Testing
- Cetuximab, Cisplatin, 5 - Fluorouracil
- Where
- 7 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Neoplasms
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
- Trial name
- IGNYTE-ESO (NCT03967223)
- Testing
- Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
- Where
- 38 sites in United States, Canada and 5 more
- Volunteers
- 103 people
- Sponsor
- USWM CT, LLC
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Osteosarcoma, Sarcoma, Ewing's
A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)
Participants with relapsed osteosarcoma that can be treated with surgery will be randomized to robatumumab administered intravenously (IV) at one of two dose levels.
- Conditions
- Osteosarcoma, Sarcoma, Ewing's, Peripheral Neuroectodermal Tumor
- Trial name
- NCT00617890
- Testing
- robatumumab
- Volunteers
- 219 people
- Sponsor
- Merck Sharp & Dohme LLC
Sarcoma, Kaposi, HIV Infections
Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals
To determine response rate, median time to tumor progression, qualitative and quantitative toxicity and reversibility of toxicity in patients with advanced refractory AIDS-associated Kaposi's sarcoma (KS) administered a 3-hour…
- Trial name
- NCT00002189
- Testing
- Paclitaxel
- Where
- United States
- Sponsor
- Baker Norton Pharmaceuticals
Solid Tumor, Soft Tissue Sarcoma
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
This clinical study is to investigate the safety and tolerability of CAR modified autologous T cells (CCT301-59) in subjects with recurrent or refractory solid tumors.
- Conditions
- Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CAR (NCT03960060)
- Testing
- CCT301-59
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Sarcoma, Soft Tissue
Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma
This study aims to explore a new therapeutic approach for advanced soft tissue sarcoma (STS) by investigating the safety, tolerability, and maximum tolerated dose (MTD)/highest tolerated dose (HTD) of DPPG2-TSL-DOX combined with…
- Trial name
- NCT05858710
- Testing
- DPPG2-TSL-DOX, Dexrazoxane
- Where
- 2 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Thermosome GmbH
Advanced Soft-tissue Sarcoma
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS
This is an Interventional Study in Advanced Soft Tissue Sarcomas (ASTS). It is a Phase 1b, open-label, dose-escalation clinical study evaluating the safety of camsirubicin with prophylactic pegfilgrastim in the treatment of…
- Trial name
- NCT05043649
- Testing
- Camsirubicin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Monopar Therapeutics
Sarcoma
MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
This study will evaluate the safety and preliminary efficacy of Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) in combination with Apatinib and/or Camrelizumab in patients with advanced bone and soft-tissue sarcoma.
- Trial name
- NCT04074564
- Testing
- MASCT-I, Camrelizumab,Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- HRYZ Biotech Co.
Pediatric Malignant Solid Tumor and Epithelioid Sarcoma
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
This is a multicenter, open-label, uncontrolled Phase I/II study to evaluate the efficacy, safety, and pharmacokinetics of ONO-4538HSC in pediatric patients with malignant solid tumors and in patients with epithelioid sarcoma…
- Trial name
- NCT07734116
- Testing
- ONO-4538HSC
- Where
- 15 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Relapsed / Refractory Osteosarcoma
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma.
- Trial name
- NCT07357519
- Testing
- LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Lantheus Medical Imaging
Soft Tissue Sarcoma
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.
- Trial name
- NCT01440088
- Testing
- TH-302 in Combination with Doxorubicin, Doxorubicin
- Where
- 92 sites in United States, Austria and 11 more
- Volunteers
- 640 people
- Sponsor
- Threshold Pharmaceuticals
Malignant Melanoma, Angiosarcoma
Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma
Among skin malignancies, patients with malignant melanoma or angiosarcoma are treated with BNCT using CICS-1 and SPM-011 (borofalan (10B)). Through this trial, safety and appropriate treatment dose will be determined.
- Trial name
- NCT04293289
- Testing
- CICS-1 (investigational device),SPM-011(investigational drug)
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Cancer Intelligence Care Systems, Inc.
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.